Ferring Presents New Phase 3b Safety and Effectiveness Data for Recurrent C. Diff Patients Receiving REBYOTA® (fecal microbiota, live – jslm) Via Colonoscopy, and Additional Analyses at DDW
BioSpace - 05 May 2025Ferring Presents New Phase 3b Safety and Effectiveness Data for Recurrent C. Diff Patients Receiving REBYOTA® (fecal microbiota, live – jslm) Via Colonoscopy, and Additional Analyses at DDW ...